Topic: Eugene Melnyk
Eugene Melnyk Hurray for Senators owner Eugene Melnyk. He's right. Melnyk told Sportsnet Radio in Toronto Tuesday that any NHL player delivering a...
Two mayors ... more gaffes. This is my weekly column that appears in the Citizen on Wednesdays: ---- Here they are ... the award-winning local...
Valeant Pharmaceuticals International Inc. said Monday that Chairman Bill Wells resigned from the board to pursue other interests.The change comes as Valeant deals with setbacks for two of its most advanced drug candidates.The Canadian drugmaker said board member Robert Ingram ...
By Wayne Scanlan. . OTTAWA — Phones are ringing. Texts are flying. Email inboxes are filling up (Subject: Senators are brutal!).. . Hockey fans are...
Nearly four years after raising a big stink - and filing a group of $4.6 billion lawsuits - over allegations that research analysts and hedge funds...
Canadian drugmaker Biovail Corp. and Valeant Pharmaceuticals International said Monday they are forming a new company under the Valeant name, capping Biovail's recovery from falling sales and financial scandals.Combined, the companies had $1.65 billion in revenue in 2009. They ...
The founder and former CEO of Biovail Corp. reported Monday that he has divested his shares in the Canadian drug maker. Biovail and Melnyk neither admitted nor denied the agency's allegations under the settlements. Melnyk said in a news release Monday ...
Ottawa Senators owner Eugene Melnyk fires back at Blackberry billionaire Jim BalsillieOttawa Senators owner Eugene Melnyk is firing back at BlackBerry billionaire Jim Balsillie.Melnyk has released a statement Thursday that reads like an open letter to Balsillie. He addressed claims by ...
Ottawa Senators president and CEO Roy Mlakar leaving job at end of JuneOttawa Senators president and CEO Roy Mlakar will not return when his contract expires at the end of the month, owner Eugene Melnyk said Monday.Melnyk has promoted chief operating ...
Biovail Corp founder Eugene Melnyk has agreed to pay a $1 million fine in a case brought by the U.S. securities regulator over the Canadian drugmaker's accounting practices, according to court documents. 'At issue in the claim resolved was whether ...
